Long-term safety and efficacy of cabergoline for the treatment of idiopathic restless legs syndrome: results from an open-label 6-month clinical trial.
OBJECTIVE
To assess the safety and efficacy of cabergoline in the treatment of idiopathic restless legs syndrome (RLS) patients.


METHODS
Open-label intervention study for 26 weeks; no control group.


METHODS
302 patients (73% women, aged 61 +/- 11 years) from 37 German neurologic outpatient departments and private practices.


METHODS
Cabergoline was upwardly titrated over 4 weeks to individually optimized dosages. Median treatment duration was 181 days. The median daily dose of cabergoline was 1.5 mg.


METHODS
Drug safety was assessed by adverse events; efficacy was evaluated with the RLS-6 and the International RLS Rating Scales.


RESULTS
In 48% of the study participants, investigators reported adverse events suspected to be drug related. Most adverse events were mild and transient and related to the gastrointestinal system (nausea: 16.6%) or the central nervous system (dizziness: 7.0%, headache: 4.6%). Premature dropout from the study occurred in 54 patients (17.9%), in 17 patients (3.0%) due to a drug-related adverse event. The severity of RLS symptoms at night, at bedtime, and during the day, as well as the International RLS Rating Scale total score improved during therapy. Satisfaction with sleep was increased (all P values < .001). In 5% of all patients, RLS symptoms worsened, and in a further 6.3%, response to therapy was poor. In 9 patients (3.0%) between 1 and 3 criteria for augmentation were noted.


CONCLUSIONS
Long-term therapy with cabergoline is a safe and well-tolerated treatment option for the great majority of patients with idiopathic RLS. The treatment was efficacious both for nighttime and daytime symptoms in this indication and may carry a low risk of augmentation.
Helios-Kliniken, Clinic of Neurology, Sleep Laboratory, Schwerin, Germany. hbenes@schwerin.helios-kliniken.de
Heike
H
Benes
Claus R
CR
Heinrich
Michael A
MA
Ueberall
Ralf
R
Kohnen
D000077465:Cabergoline; D018491:Dopamine Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D004873:Ergolines / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012148:Restless Legs Syndrome / Q000175:diagnosis / Q000188:drug therapy*; D012720:Severity of Illness Index; D013995:Time; D013997:Time Factors
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline